Literature DB >> 18611569

Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals.

S L Chan1, W W Yew, J H Porter, K P McAdam, B W Allen, J M Dickinson, G A Ellard, D A Mitchison.   

Abstract

Bioavailability was measured by rifapentine (RPE) serum concentrations and by the urinary ratio between RPE and creatinine, in specimens obtained 4-50 h after 600 mg RPE preceded by food. The bioavailabilities of RPEs manufactured in China and by a Western manufacturer were similar after a standard English breakfast, and serum concentrations were also similar to those obtained in an earlier Italian study following a complex meal. Although absorption of RPE was unsatisfactory after lipid-rich biscuits or shortbread, absorption after egges and toast was excellent and was nearly as good after a fast-food sandwich. The urinary measure of bioavailability at 26 h appeared as efficient as peak serum estimations at 6, 8 and 26 h. Fast-food sandwiches are being taken before RPE in a current clinical trial of Chinese RPE in Hong Kong.

Entities:  

Year:  1994        PMID: 18611569     DOI: 10.1016/0924-8579(94)90054-x

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.

Authors:  A C Keung; R C Owens; M G Eller; S J Weir; D P Nicolau; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

4.  High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Authors:  Susan E Dorman; Payam Nahid; Ekaterina V Kurbatova; Stefan V Goldberg; Lorna Bozeman; William J Burman; Kwok-Chiu Chang; Michael Chen; Mark Cotton; Kelly E Dooley; Melissa Engle; Pei-Jean Feng; Courtney V Fletcher; Phan Ha; Charles M Heilig; John L Johnson; Erica Lessem; Beverly Metchock; Jose M Miro; Nguyen Viet Nhung; April C Pettit; Patrick P J Phillips; Anthony T Podany; Anne E Purfield; Kathleen Robergeau; Wadzanai Samaneka; Nigel A Scott; Erin Sizemore; Andrew Vernon; Marc Weiner; Susan Swindells; Richard E Chaisson
Journal:  Contemp Clin Trials       Date:  2020-01-22       Impact factor: 2.226

Review 5.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

6.  Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.

Authors:  Radojka M Savic; Yanhui Lu; Erin Bliven-Sizemore; Marc Weiner; Eric Nuermberger; William Burman; Susan E Dorman; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

7.  Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.

Authors:  Simbarashe P Zvada; Jan-Stefan Van Der Walt; Peter J Smith; P Bernard Fourie; Giorgio Roscigno; Denis Mitchison; Ulrika S H Simonsson; Helen M McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

Review 8.  Rifapentine.

Authors:  B Jarvis; H M Lamb
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

9.  Single-dose pharmacokinetics of rifapentine in women.

Authors:  A C Keung; M G Eller; S J Weir
Journal:  J Pharmacokinet Biopharm       Date:  1998-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.